3HP-2827 not checked
3H (Suzhou) Pharmaceuticals Co., Ltd.
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “3HP-2827 will be administered orally once daily in 28-day cycles.”In the company’s words, NCT06378593 on ClinicalTrials.gov
- Tested for
- Solid Tumors With FGFR2 Alterations, Adult (2 trials)
- Main trialPhase 1/2
- “The study is being conducted to evaluate the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of 3HP-2827 in the treatment of unresectable or metastatic solid tumors with FGFR2 alterations.”In the company’s words, NCT06378593 on ClinicalTrials.gov
Other drugs for Solid Tumors With FGFR2 Alterations, Adult
- AvelumabEMD Serono Research & Development Institute, Inc. · Phase 3
- AlectinibRoche · Phase 3
- AtezolizumabRoche · Phase 3
- AU-011Aura Biosciences · Phase 3
- BevacizumabRoche · Phase 3
- CadonilimabAkeso · Phase 3
Coming up2
- Mar 2028Phase 1 trial completes · ClinicalTrials.gov
- 16 Jun 2028Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Recruiting | 16 Jun 2028 | A Study of 3HP-2827 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations | |
| Phase 1Not yet recruiting | Mar 2028 | A First-in-human Study of 3HP-2827 in Patients With Unresectable or Metastatic Solid Tumors With FGFR2 Alterations |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026